Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Busan
Clinical trial register · South Korea

Clinical Trials in Busan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 58 Busan 23 Seongnam 19 Daegu 15 Incheon 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca50 Janssen Research & Development, LLC30 Eli Lilly and Company23 AbbVie19 Novartis Pharmaceuticals16 Clear sponsor filter
Site location
Seoul58 Busan23 Seongnam19 Daegu15 Incheon15
All 42 locations
Target enrolment
to

Trials with a site in Busan

23 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Eli Lilly and Company
Phase 3
2,001
Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam
2026-08-26
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Busan, Daegu, Daejeon, Gwangju, Gyeongsan-si, Pusan, Seoul, Wŏnju
2026-03-26
Recruiting
Eli Lilly and Company
Phase 3
7,140
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, Ulsan
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Anyang-si, Bucheon-si, Busan, Gwangju, Junggu, Seoul
2025-09-30
Recruiting
Eli Lilly and Company
Phase 1/2
68
Busan, Seoul
2025-07-30
Recruiting
Eli Lilly and Company
Phase 3
700
Bupyeong-gu, Busan, Cheongju-si, Daegu, Deagu, Eunpyeong-gu, Gangnam-gu, Goyang-si
2025-03-27
Active, closed
Eli Lilly and Company
Phase 3
1,400
Busan, Cheongju-si, Gangnam-gu, Gangseo-gu, Gwangju, Incheon, Jeju City, Namdong-gu
2024-10-24
Recruiting
Eli Lilly and Company
Phase 3
510
Busan, Gyeonggi-do, Pusan, Seongnam-si, Seoul, Suwon
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Busan, Incheon, Seongnam-si, Seoul
2024-04-26
Recruiting
Eli Lilly and Company
Phase 3
90
Busan, Daegu, Seoul
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
3,127
Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu
2023-06-05
Recruiting
Eli Lilly and Company
Phase 3
595
Busan, Cheonan-si, Daejeon, Incheon, Jeonju, Junggu, Seongnam-si, Seoul
2023-02-27
Active, closed
Eli Lilly and Company
Phase 3
15,374
Ansan-si, Busan, Seongnam, Seoul, Wŏnju
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Active, closed
Eli Lilly and Company
Phase 3
8,000
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Gyeongsan-si, Hwasun-gun, Incheon
2022-10-04
Active, closed
Eli Lilly and Company
Phase 3
152
Hwasun, Goyang-si, Seongnam, Busan, Seoul, Deagu
2021-12-20
Active, closed
Eli Lilly and Company
Phase 3
874
Cheonan-si, Namdong-gu, Suwon, Daegu, Busan, Seoul
2021-10-04
Active, closed
Eli Lilly and Company
Phase 3
996
Wŏnju, Ansan-si, Guri-si, Suwon, Gyeongsan-si, Busan, Haeundae-gu, Dongjak-gu
2020-06-22
Active, closed
Eli Lilly and Company
Phase 3
1,058
Busan, Daejeon, Gyeongsan-si, Haeundae-gu, Seoul, Wŏnju
2018-07-18
Active, closed
Eli Lilly and Company
Phase 3
5,637
Cheongju-si, Cheonan-si, Incheon, Namdong-gu, Goyang-si, Seongnam, Busan, Haeundae-gu
2017-07-12
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/busan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Busan that also match the filters currently applied.

How many clinical trials are recruiting in Busan?

12 of the 23 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Busan), 23 studies
PhaseStudiesRecruitingShare
Phase 3211091.3%
Phase 1/2114.3%
Phase 2114.3%

Most active sponsors

Lead sponsors with the most studies (Busan)
Lead sponsorStudiesRecruiting
Eli Lilly and Company2312
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.